MRI scans may fail to detect a disease-causing pituitary tumor in up to one third of children and adolescents with Cushing’s disease, a study found. In the study, patients with a negative MRI scan result were less likely to enter in remission after having surgery to remove the pituitary…
News
The National Organization for Rare Disorders, known as NORD, was named an official charity partner of the 2021 TCS New York City Marathon, which will be held Nov. 7 both in-person and online. “Supporting charitable causes and organizations are a long-standing tradition of the TCS New York City…
Analyzing small amounts of tumor DNA that end up in the bloodstream could be useful for assessing the course of Cushing’s syndrome in patients whose disease is caused by a hormone-producing tumor, a new report illustrates. In the case of a 45-year-old man in France, DNA changes “were well correlated…
The National Alliance for Caregiving, in partnership with Global Genes, has issued a free guidebook, available online, that offers resources and support for caregivers of children with rare diseases. “The Circle of Care Guidebook for Caregivers of Children With Rare and/or Serious Illnesses” was designed…
Registration is now open for Global Genes‘ 2021 RARE Patient Advocacy Summit. This year’s hybrid event will be livestreamed from California Sept. 27-29, and some seats also are available for attending the event in person in San Diego. “Here you’ll have the opportunity to connect and engage with others…
A rare case of a man with severe Cushing’s syndrome due to an adrenocorticotropic hormone (ACTH)-producing lung tumor, initially evident as a benign mass and further complicated by a history of metastatic rectal cancer, was described by scientists. “Case Report: A Challenging Localization of a Pulmonary…
CRN04894, a first-in-class, investigational oral medication to treat Cushing’s disease, demonstrated pharmacologic proof-of-concept with a dose-dependent suppression of cortisol, according to data from a Phase 1 study. CRN04894, developed by Crinetics Pharmaceuticals, is designed to block the interaction (antagonist) between the MC2R receptor, found specifically on the…
Registration is now open for the 2021 Rare Diseases and Orphan Products Breakthrough Summit, which will be held virtually Oct. 18–19. The event, also known as the National Organization for Rare Disorders (NORD) Summit, brings the rare disease community together to network and discuss developments in treatments and research…
Loss of muscle mass, also known as sarcopenia, is common among people with Cushing’s syndrome in long-term remission, and is associated with a poorer quality of life, a study reported. Its researchers also found the Sarcopenia Index, a blood test that can be used to estimate a patient’s muscle…
More than 600 people participated in the 10th annual Rare Disease Week on Capitol Hill 2021, held virtually July 14–22, to advocate for the rare disease community. Hosted by the EveryLife Foundation’s Rare Disease Legislative Advocates (RDLA) program, the event brings together community members from across the U.S. to…
Recent Posts
- Blood thinner rivaroxaban prevents clots in ACTH-dependent Cushing’s
- Surgery offers best cortisol control for adrenal Cushing’s syndrome
- Turning negatives into positives keeps me out of the ‘why me’ pit
- Common Cushing’s test may miss aggressive tumors in some patients
- Weak bones, fractures prevalent in Cushing’s syndrome: Analysis
- We’re preparing to finally bring our newborn daughter home
- Surgery brings Cushing’s remission to 60% of patients over 20 years: Study
- New Cushing’s disease treatment option reaches Canada with Isturisa
- I’m trying to be more honest about how medical trauma affects me
- CRH test may replace invasive method in diagnosing Cushing’s disease: Study